Stock DNA
Pharmaceuticals & Biotechnology
CHF 926 Million ()
NA (Loss Making)
NA
0.00%
-1.05
4.71%
-0.82
Revenue and Profits:
Net Sales:
72 Million
(Quarterly Results - Jun 2025)
Net Profit:
-11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.08%
0%
15.08%
6 Months
100.48%
0%
100.48%
1 Year
203.65%
0%
203.65%
2 Years
113.55%
0%
113.55%
3 Years
-69.21%
0%
-69.21%
4 Years
-74.54%
0%
-74.54%
5 Years
-83.43%
0%
-83.43%
Idorsia Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
27.11%
EBIT Growth (5y)
10.78%
EBIT to Interest (avg)
-28.79
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.95
Sales to Capital Employed (avg)
0.25
Tax Ratio
0.30%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.83
EV to EBIT
-11.99
EV to EBITDA
-13.42
EV to Capital Employed
-64.75
EV to Sales
9.65
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot : Jun 2023
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
72.20
58.90
22.58%
Operating Profit (PBDIT) excl Other Income
-2.40
-20.70
88.41%
Interest
8.70
7.50
16.00%
Exceptional Items
-0.30
-0.60
50.00%
Consolidate Net Profit
-11.40
63.10
-118.07%
Operating Profit Margin (Excl OI)
-101.40%
-425.20%
32.38%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 22.58% vs -1.67% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -118.07% vs 175.12% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
112.50
152.40
-26.18%
Operating Profit (PBDIT) excl Other Income
-325.60
-524.00
37.86%
Interest
20.10
20.70
-2.90%
Exceptional Items
-26.10
-19.20
-35.94%
Consolidate Net Profit
-263.80
-297.90
11.45%
Operating Profit Margin (Excl OI)
-3,053.00%
-3,563.70%
51.07%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -26.18% vs 56.95% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 11.45% vs 64.02% in Dec 2023
About Idorsia Ltd. 
Idorsia Ltd.
Pharmaceuticals & Biotechnology
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Company Coordinates 
Company Details
Hegenheimermattweg 91 , ALLSCHWIL None : 4123
Registrar Details






